{"entity":{"id":"nct05323955","kind":"trial","name":"Tucatinib after isolated brain progression","aka":["Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib"],"tldr":"This study adds tucatinib after local treatment for cancer progression in the brain while continuing selected HER2-directed therapy. It follows further progression in people whose cancer outside the brain remains controlled.","summary":"This study adds tucatinib after local treatment for cancer progression in the brain while continuing selected HER2-directed therapy. It follows further progression in people whose cancer outside the brain remains controlled.\n\nInterventional study registered as NCT05323955, sponsored by Carey Anders, M.D.. Registry phase: 2. Registry enrollment is 48 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT05323955","url":"https://clinicaltrials.gov/study/NCT05323955"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT05323955"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pertuzumab","trastuzumab","trastuzumab-emtansine","tucatinib"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05323955","phase":"2","setting":"Advanced HER2-positive breast cancer with isolated intracranial progression","sponsor":"Carey Anders, M.D.","participation":[{"nct":"NCT05323955","source":"https://clinicaltrials.gov/study/NCT05323955","fetchedAt":"2026-10-10T20:54:22.593829Z","studySha256":"d7e90931b302aed087155c9b6829641405f755a50bcade50e24fc2d5d79adf45","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-23","leadSponsor":"Carey Anders, M.D.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":48,"enrolmentType":"ESTIMATED","siteCount":8,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2023-03-23","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05323955/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}